Evaluation of platelet function in essential thrombocythemia under different analytical conditions
Research article published in Platelets (2020)
Abstract
Background. Studies of platelet aggregation (PA) in essential thrombocythemia (ET) reported contrasting results, likely due to differences in analytical conditions.Objective. We investigated platelet aggregation using different techniques and analytical conditions.Patients and Methods. PA was studied by light-transmission aggregometry (LTA) in platelet-rich plasma (PRP) and impedance aggregometry in PRP and whole blood (WB). ADP, collagen, thrombin receptor activating peptide (TRAP-14) and adrenaline were used as agonists. Since ET patients (n = 41) were on treatment with aspirin (100 mg/d), healthy controls (n = 29) were given aspirin (100 mg/d) for 5 days before testing: therefore, thromboxane A2-independent PA was tested in all subjects. Blood samples were collected in citrate (C) [low Ca2+] or lepirudin (L) [physiological Ca2+]; platelet count was adjusted to 250 x 109/L in a set of C-PRP (adjusted C-PRP) and left unmodified in the other samples.Results. Results of PA in 17 ET patients who were poor responders to aspirin (high serum thromboxane B2 levels) were not included in the analysis. With LTA, PA in ET was lower than in controls in adjusted C-PRP and normal in native C-PRP and L-PRP. With impedance aggregometry, PA in L-PRP and L-WB tended to be higher in ET than in controls. Platelet serotonin and ADP contents were reduced in ET. The percentages of circulating platelets expressing P-selectin and platelet-leukocyte hetero-aggregates were higher in ET.Conclusions. Analytical conditions dramatically affect in vitro PA of ET patients, which appears defective under the least physiological conditions and normal/supranormal under conditions that are closer to the physiological.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Este estudio examinó la agregación plaquetaria en 41 pacientes con trombocitemia esencial frente a 29 controles sanos tratados con aspirina utilizando múltiples técnicas, y encontró que los resultados dependen en gran medida de las condiciones analíticas: la agregación pareció defectuosa bajo las condiciones menos fisiológicas (plasma rico en plaquetas citratado y ajustado por recuento) pero normal o supranormal bajo condiciones más cercanas a la fisiología. De interés directo para ASH, los investigadores utilizaron lepirudin (un anticoagulante recombinante de hirudin de sanguijuela) precisamente para preservar el calcio fisiológico durante las pruebas, ilustrando cómo un inhibidor de trombina derivado de sanguijuela sirve como un anticoagulante de grado de investigación cuyas propiedades difieren significativamente del citrato. La advertencia es que se trata de una comparación de laboratorio ex vivo de las condiciones de ensayo en una población de pacientes específica, no un estudio de resultados clínicos o terapéutico de la terapia con sanguijuelas, por lo que su valor para la hirudoterapia es metodológico más que clínico.
Citación
Evaluation of platelet function in essential thrombocythemia under different analytical conditions.
Lussana et al. · Platelets, 2020
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026